Skip to main content

Conditions · The patch shortage · 100% virtual

Your estradiol patch isn’t in stock. Here’s how I handle it.

The short answer

As of September 2026 there is a real supply problem with estradiol patches, even though the FDA’s shortage database does not list one — the pharmacists’ list does. If your pharmacy can’t fill it, you do not have to stop hormone therapy. Gel, spray, a systemic vaginal ring and oral estradiol are all available, and switching is a prescription change, not starting over.

Last updated September 1, 2026

★★★★★ 5.0 stars, 22 verified patient reviews →

Why your pharmacy says one thing and the FDA says another

This is the part that makes women feel gaslit, so let me explain it plainly. The FDA’s official drug shortage database does not list estradiol transdermal systems at all. The American Society of Health-System Pharmacists — the list most hospital and retail pharmacists actually work from — has listed estradiol transdermal systems since January 2026, with more than a dozen products across five manufacturers affected. Both are telling the truth about their own methods. The FDA judges shortage against historic aggregate demand data, which lags badly when demand jumps suddenly. The pharmacists’ list is built from what practitioners and patients report from the counter, in something close to real time. You are not imagining it, and your pharmacist is not making it up.

The cause is not mysterious. In November 2025 the FDA asked manufacturers to remove most of the boxed warning from menopausal hormone therapy products, and prescribing rose sharply — one large health-system dataset put estrogen patch use up about 184% since 2023, and up roughly a fifth in the seven months after the announcement alone. Patches are low-margin generics. New production lines take years to build, batches are planned months ahead, and long-term supply contracts limit how fast anyone can pivot. One manufacturer’s public statement was that the November change created demand that cannot fully be met at present. Estimates of how long this lasts range from about a year to about three, depending on who is asked — nobody actually knows.

Here is what I want you to take from that: this is a manufacturing and distribution problem, not a signal that patches became dangerous or that your therapy was a mistake. Nothing about the medicine changed.

The practical question is what to do this month. There are four routes that deliver estradiol systemically, and none of them requires starting over — you have already established that you tolerate estrogen. A different manufacturer’s patch, a different strength combination, or a different wear schedule (twice-weekly instead of once-weekly, or the reverse) is usually the first thing to try, because it is the smallest change. After that, gel, spray, a three-month systemic vaginal ring, or an oral tablet are all real options, and the choice is not arbitrary — it depends on your clotting history, your cholesterol, and what your insurance will actually cover, which is often the deciding factor.

One important caution about switching to oral. Oral estradiol goes through the liver first, and in large observational studies that is associated with a higher risk of blood clots than the skin routes, which appear not to carry that increase. If you have a personal or family history of clots, oral is the route I am most reluctant to move you to, and the vaginal ring or gel is a better answer. If your cholesterol is the bigger problem, the calculus can run the other way. That is a conversation with numbers in it, not a coin flip.

What each route looks like if the patch is unavailable

Route

A different patch — another manufacturer, another strength, or two lower-dose patches

What to know about switching to it

The smallest change and usually the first thing to try. Two lower-dose patches worn together is a recognized workaround when one strength is out. Where you put it matters: the buttock delivers roughly 25% higher peak levels than the abdomen.

Route

Estradiol gel

What to know about switching to it

Applied daily to the skin, so it keeps the non-oral route and its lower clot signal. Published equivalence tables are explicitly approximate — no two products have been compared head to head — so expect a recheck of symptoms rather than a perfect swap.

Route

Transdermal spray

What to know about switching to it

Also daily, also skin-route. Worth knowing that it plateaus: in the product’s own pharmacokinetic data, three sprays produce essentially the same blood level as two. It tops out at roughly a low-to-mid-strength patch, so it is not the answer if you were on a high dose.

Route

Systemic vaginal ring (not the low-dose local one)

What to know about switching to it

Inserted every three months, which some women prefer to a daily task. On the label’s own numbers this is the closest match to a standard patch — mean estradiol around 41 pg/mL for the patch versus about 41 for the ring at its lower strength. Note this is a different product from the low-dose local ring used for vaginal symptoms.

Route

Oral estradiol

What to know about switching to it

Widely available and usually the cheapest. But it passes through the liver first, and observational data associate oral estrogen with increased clot risk where the skin routes do not. It also produces a different estrone-to-estradiol balance. I would consider it, and I would not choose it first if you have any clot history.

Route

Compounded estradiol from a compounding pharmacy

What to know about switching to it

Not where I would go while approved gel, spray, ring and tablets are still on the shelf. A supply gap is one of the situations major bodies accept compounding for — but only when the commercial product is genuinely unavailable, and right now other commercial products are not.

What I weigh before prescribing anything

Your clotting history

This is the single biggest input into which route I pick. Personal or family history of DVT or pulmonary embolism, a known clotting disorder, or recent immobilization all push hard toward keeping you on a skin route — gel, spray, or the ring — rather than moving to oral because it happens to be in stock.

What your insurance actually covers

This is not a footnote. Patches are frequently the only route covered at a reasonable copay, and gel or spray can be several times the cost. It is worth calling before we write, because the plan’s answer sometimes decides this more than the medicine does.

The dose you were actually stable on

Equivalence tables between routes are approximations published with that caveat attached. I write the closest match, then check in with you at a few weeks — not because we are guessing wildly, but because absorption genuinely varies between people and there is no trial that settled it.

Whether the symptoms came back or never fully went

A supply interruption is an accidental natural experiment. If you went two weeks without and felt fine, that is worth knowing. If night sweats returned on day three, that is also worth knowing. Both change what I do next.

Whether you still need a progestogen

If you have a uterus and you switch estrogen routes, the endometrial protection still has to be there. This gets dropped surprisingly often in a scramble to find any estrogen at all, and it is the one part of the regimen I will not let go missing.

Questions worth asking any doctor — including me

Bring these to your next appointment, wherever it is. A doctor who welcomes them is a good sign.

  1. Is there a different manufacturer or strength of the same patch my pharmacy can get?
  2. Can I use two lower-dose patches instead of the one strength that’s out of stock?
  3. Given my clot history and my cholesterol, which route would you pick for me — and why that one?
  4. What dose of gel, spray, ring or tablet is the closest match to what I was on?
  5. Will my insurance cover the alternative, and can we check before we send it?
  6. When should I check back in to see whether the new route is holding my symptoms?
  7. If I have a uterus, does my progesterone dose need to change when the estrogen route changes?

Print these — and the questions for every other condition — on one page →

Questions I hear about this

Is there actually an estradiol patch shortage?

It depends which list you read, and both lists are honest. The FDA’s drug shortage database does not list estradiol transdermal systems. The American Society of Health-System Pharmacists has listed them since January 2026, covering more than a dozen products from five manufacturers. The FDA measures shortage against historic aggregate supply-and-demand data, which lags a sudden demand spike; the pharmacists’ list is compiled from what practitioners and patients report as it happens. The FDA Commissioner’s own public description in May 2026 was that industry had kept up “but barely” and had not met the criteria for the shortage list. So: real at the counter, not on the federal list.

Can I stretch my patch and wear it longer to make it last?

I would not, and I want to be specific about why rather than just saying no. There is no published pharmacokinetic study of wearing an estradiol patch past its labeled interval — this is an evidence vacuum, not a debate. What the labels do show is that a weekly patch is already at its lowest blood level at the end of day seven; there is no reserve left to draw on by leaving it on. Stretching a twice-weekly patch to a week doubles the interval with no data at all. If you are running short, tell me before you ration — switching routes is a better answer than a falling level you cannot see.

Can I cut a patch in half?

Only some of them, and only some of the time. Matrix patches, where the hormone is dispersed through the adhesive, can be cut; reservoir patches leak and are ruined. There is one study measuring hormone content in cut patches stored for a month, which found most brands held their content, though one lost more than half at higher storage temperatures — and it measured drug content in a lab, not blood levels in women. So it is not nothing, but it is thin, and the brands studied were European. Ask your pharmacist which type yours is before you cut anything, and do not cut one as a routine strategy.

Should I switch to compounded estrogen while the patches are out?

Not as a first move. A 2020 National Academies review found a lack of rigorous evidence of safety and effectiveness for compounded hormone therapy and called widespread use a public health concern; ACOG’s 2023 guidance says approved products are recommended over compounded ones. Compounding is genuinely appropriate in specific situations — a true allergy to an ingredient, or when the commercial product is unavailable. A patch being out of stock while approved gel, spray, ring and tablets are all still stocked is not that situation. Compounding pharmacies are marketing hard into this shortage; that is worth knowing before you get the pitch.

How long is this going to last?

Honestly, nobody knows, and I would be suspicious of anyone who says otherwise. Industry sources quoted in April 2026 suggested it could run up to three years. The medical director of The Menopause Society was more optimistic, saying manufacturers are increasing production and things should be better by the end of the year. The disagreement is real and it reflects genuine uncertainty about how fast generic manufacturing can expand. Plan as though it may last a while, which mostly means: do not wait until you have two days left to sort out an alternative.

Do I have to start over if I switch routes?

No. You already know you tolerate estrogen and roughly what dose controls your symptoms — that information carries across. What changes is absorption, and because the published equivalence tables between routes are approximations rather than trial-derived conversions, I plan on a check-in a few weeks after a switch. That is a dose adjustment, not starting from zero.

Should I just stop taking it until this blows over?

That is your decision to make, and I would want you to make it deliberately rather than by default because a pharmacy said no. Stopping abruptly commonly brings symptoms back, sometimes sharply. If you were on hormone therapy for moderate or severe symptoms and it was working, an interruption is a real loss, and there is almost always another route available. If you have been wondering whether you still need it, this is a reasonable moment to have that conversation on purpose — but have it, rather than letting a supply problem decide it for you.

Sources

Related here: Menopause & hormone care · What to expect on progesterone · Conditions I evaluate for

Bring me this history — it's the part of the visit I care about most

One visit, $150, paid after we talk. No subscription, no package — and if I'm not the right physician for your situation, I'll say so. If medication is right for you, I try your insurance first.

I'm licensed in 15 states: Alabama, California, Florida, Georgia, Illinois, Indiana, Mississippi, Missouri, New Jersey, New York, Oklahoma, South Carolina, Tennessee, Texas, Washington. Please check yours before booking.

Book my $150 visit

Not sure yet? Ask me a question first.